Discovery of RP-1664: A First-in-Class Orally Bioavailable, Selective PLK4 Inhibitor. - Vallée F; Casás-Selves M; Bubenik M; Duplessis M; Sow B; Suarez C; Sangiorgi B; Li L; Hyer M; Papp R; Leclaire ME; Perryman AL; et al. (Journal of medicinal chemistry, 2025)